Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lipella Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
LIPO
Nasdaq
2836
www.lipella.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lipella Pharmaceuticals Inc.
Top Midday Gainers
- Feb 11th, 2025 6:34 pm
Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment
- Feb 11th, 2025 6:10 pm
Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes
- Feb 11th, 2025 3:52 pm
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
- Feb 11th, 2025 10:46 am
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
- Feb 6th, 2025 11:00 am
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement
- Jan 10th, 2025 6:24 pm
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
- Dec 3rd, 2024 1:30 pm
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
- Nov 21st, 2024 10:30 am
Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023)
- Nov 17th, 2024 1:47 pm
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
- Nov 12th, 2024 10:30 am
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
- Nov 1st, 2024 8:30 pm
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
- Oct 29th, 2024 12:30 pm
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
- Oct 15th, 2024 9:00 am
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
- Oct 9th, 2024 2:47 pm
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
- Sep 25th, 2024 12:30 pm
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
- Sep 24th, 2024 12:00 pm
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
- Aug 27th, 2024 12:00 pm
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
- Aug 22nd, 2024 9:00 am
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
- Aug 21st, 2024 9:00 am
Lipella Pharmaceuticals Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.27 loss in 2Q 2023)
- Aug 16th, 2024 12:30 pm
Scroll